Cargando…

Dual Primary Cancer Patients With Lung Cancer as a Second Primary Malignancy: A Population-Based Study

BACKGROUND: Research on patients with lung cancer as a second primary malignancy (LCSPM) remains limited. This study aims to determine the clinical characteristics, prognosis, and temporal relationship of other cancers to lung cancer in these patients. METHODS: This study retrospectively analyzed 34...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Congkuan, Yu, Donghu, Wang, Yujin, Wang, Qingwen, Guo, Zixin, Huang, Jingyu, Li, Sheng, Hu, Weidong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7649344/
https://www.ncbi.nlm.nih.gov/pubmed/33194578
http://dx.doi.org/10.3389/fonc.2020.515606
_version_ 1783607306185867264
author Song, Congkuan
Yu, Donghu
Wang, Yujin
Wang, Qingwen
Guo, Zixin
Huang, Jingyu
Li, Sheng
Hu, Weidong
author_facet Song, Congkuan
Yu, Donghu
Wang, Yujin
Wang, Qingwen
Guo, Zixin
Huang, Jingyu
Li, Sheng
Hu, Weidong
author_sort Song, Congkuan
collection PubMed
description BACKGROUND: Research on patients with lung cancer as a second primary malignancy (LCSPM) remains limited. This study aims to determine the clinical characteristics, prognosis, and temporal relationship of other cancers to lung cancer in these patients. METHODS: This study retrospectively analyzed 3465 patients with dual primary cancers from the 5253 patients with LCSPM retrieved from the Surveillance, Epidemiology and End Results (SEER) database from 2010 to 2015. RESULTS: 2285 eligible patients were further analyzed in this study cohort with 59.3% of 1-year OS, 34.7% of 3-year OS, and 25.2% of 5-year OS. The most common first primary cancer (FPC) in dual primary cancer patients with LCSPM was prostate cancer, followed by female breast cancer and urinary bladder cancer. In the entire study population, the median interval between the two primary malignancies was 21 months (range: 3.5–52 months). Age, sex, FPC location, surgery, stage, and histology of lung cancer were regarded as independent prognostic factors for these patients. The prognosis of patients with urinary bladder cancer as FPC was the worst in the univariate (p = 0.024) and multivariate (p < 0.001) Cox analyses. Lung cancer-directed surgery could significantly improve long-term survival (HR = 0.22, p < 0.001). Additionally, the C-index of the established nomogram with acceptable calibration curves was 0.760 (95% CI: 0.744–0.776) in the training cohort and was 0.759 (95% CI: 0.737–0.781) in the validation cohort, showing an ideal model discrimination ability. The corresponding decision curve analysis (DCA) indicated the nomogram had relatively ideal clinical utility. CONCLUSIONS: Cancer patients still have the risk of developing a new primary lung cancer. Close, lifelong follow-up is recommended for all these patients. Early detection for surgical treatment will significantly improve the prognosis of dual primary cancer patients with LCSPM. The nomogram developed to predict 1-, 3-, and 5-year OS rates has relatively good performance.
format Online
Article
Text
id pubmed-7649344
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-76493442020-11-13 Dual Primary Cancer Patients With Lung Cancer as a Second Primary Malignancy: A Population-Based Study Song, Congkuan Yu, Donghu Wang, Yujin Wang, Qingwen Guo, Zixin Huang, Jingyu Li, Sheng Hu, Weidong Front Oncol Oncology BACKGROUND: Research on patients with lung cancer as a second primary malignancy (LCSPM) remains limited. This study aims to determine the clinical characteristics, prognosis, and temporal relationship of other cancers to lung cancer in these patients. METHODS: This study retrospectively analyzed 3465 patients with dual primary cancers from the 5253 patients with LCSPM retrieved from the Surveillance, Epidemiology and End Results (SEER) database from 2010 to 2015. RESULTS: 2285 eligible patients were further analyzed in this study cohort with 59.3% of 1-year OS, 34.7% of 3-year OS, and 25.2% of 5-year OS. The most common first primary cancer (FPC) in dual primary cancer patients with LCSPM was prostate cancer, followed by female breast cancer and urinary bladder cancer. In the entire study population, the median interval between the two primary malignancies was 21 months (range: 3.5–52 months). Age, sex, FPC location, surgery, stage, and histology of lung cancer were regarded as independent prognostic factors for these patients. The prognosis of patients with urinary bladder cancer as FPC was the worst in the univariate (p = 0.024) and multivariate (p < 0.001) Cox analyses. Lung cancer-directed surgery could significantly improve long-term survival (HR = 0.22, p < 0.001). Additionally, the C-index of the established nomogram with acceptable calibration curves was 0.760 (95% CI: 0.744–0.776) in the training cohort and was 0.759 (95% CI: 0.737–0.781) in the validation cohort, showing an ideal model discrimination ability. The corresponding decision curve analysis (DCA) indicated the nomogram had relatively ideal clinical utility. CONCLUSIONS: Cancer patients still have the risk of developing a new primary lung cancer. Close, lifelong follow-up is recommended for all these patients. Early detection for surgical treatment will significantly improve the prognosis of dual primary cancer patients with LCSPM. The nomogram developed to predict 1-, 3-, and 5-year OS rates has relatively good performance. Frontiers Media S.A. 2020-10-26 /pmc/articles/PMC7649344/ /pubmed/33194578 http://dx.doi.org/10.3389/fonc.2020.515606 Text en Copyright © 2020 Song, Yu, Wang, Wang, Guo, Huang, Li and Hu http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Song, Congkuan
Yu, Donghu
Wang, Yujin
Wang, Qingwen
Guo, Zixin
Huang, Jingyu
Li, Sheng
Hu, Weidong
Dual Primary Cancer Patients With Lung Cancer as a Second Primary Malignancy: A Population-Based Study
title Dual Primary Cancer Patients With Lung Cancer as a Second Primary Malignancy: A Population-Based Study
title_full Dual Primary Cancer Patients With Lung Cancer as a Second Primary Malignancy: A Population-Based Study
title_fullStr Dual Primary Cancer Patients With Lung Cancer as a Second Primary Malignancy: A Population-Based Study
title_full_unstemmed Dual Primary Cancer Patients With Lung Cancer as a Second Primary Malignancy: A Population-Based Study
title_short Dual Primary Cancer Patients With Lung Cancer as a Second Primary Malignancy: A Population-Based Study
title_sort dual primary cancer patients with lung cancer as a second primary malignancy: a population-based study
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7649344/
https://www.ncbi.nlm.nih.gov/pubmed/33194578
http://dx.doi.org/10.3389/fonc.2020.515606
work_keys_str_mv AT songcongkuan dualprimarycancerpatientswithlungcancerasasecondprimarymalignancyapopulationbasedstudy
AT yudonghu dualprimarycancerpatientswithlungcancerasasecondprimarymalignancyapopulationbasedstudy
AT wangyujin dualprimarycancerpatientswithlungcancerasasecondprimarymalignancyapopulationbasedstudy
AT wangqingwen dualprimarycancerpatientswithlungcancerasasecondprimarymalignancyapopulationbasedstudy
AT guozixin dualprimarycancerpatientswithlungcancerasasecondprimarymalignancyapopulationbasedstudy
AT huangjingyu dualprimarycancerpatientswithlungcancerasasecondprimarymalignancyapopulationbasedstudy
AT lisheng dualprimarycancerpatientswithlungcancerasasecondprimarymalignancyapopulationbasedstudy
AT huweidong dualprimarycancerpatientswithlungcancerasasecondprimarymalignancyapopulationbasedstudy